Massachusetts Society of Clinical Oncologists - Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
Drug Updates
Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment

Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment

24 Jun 2022 7:39 AM | Katy Monaco (Administrator)

The NCCN released new Kidney Cancer guidelines (v1.2023) on June 17th and has elevated Fotivda (tivozanib) to be the only Category 1 recommended regimen, for patients that have failed 2 or more systemic treatments. More Information. Full Prescribing Information.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org